Uncategorized

Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany

Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, announced that three German-based companies have selected ColoAlert®, the Company’s highly efficacious and easy-to-use screening test for colorectal cancer into their respective corporate health programs.

Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany Read More »

Scroll to Top